akr1a1a Antibody

What is AKR1A1 and what is its primary function in cellular metabolism?

AKR1A1 (aldo-keto reductase family 1 member A1) is an enzyme that catalyzes the NADPH-dependent reduction of a wide variety of carbonyl-containing compounds to their corresponding alcohols. It displays enzymatic activity towards endogenous metabolites such as aromatic and aliphatic aldehydes, ketones, monosaccharides, and bile acids, with a preference for negatively charged substrates like glucuronate and succinic semialdehyde . One of its principal functions is acting as a detoxifying enzyme by reducing a range of toxic aldehydes, including acrolein, methylglyoxal, and 3-deoxyglucosone, which are particularly relevant under hyperglycemic conditions where these compounds can reach cytotoxic levels .

What are the recommended applications for AKR1A1 antibodies?

AKR1A1 antibodies have been validated for multiple research applications with specific recommended protocols. The following table summarizes the recommended applications and dilutions for a commonly used AKR1A1 antibody:

It is recommended that researchers titrate the antibody in each testing system to obtain optimal results, as sample-dependent variations may occur . For IHC applications, antigen retrieval with TE buffer pH 9.0 is suggested, although citrate buffer pH 6.0 may be used as an alternative .

How do zebrafish and mammalian AKR1A1 orthologs compare functionally?

In zebrafish, two orthologous genes to human AKR1A1 have been identified: akr1a1a and akr1a1b. Research indicates that Akr1a1a, like its mammalian counterpart, plays a crucial role in the detoxification of reactive carbonyl species, particularly acrolein. Studies using akr1a1a knockout zebrafish models have demonstrated that loss of this enzyme leads to impaired detoxification and accumulation of acrolein in vivo . While Akr1a1a focuses primarily on detoxification functions, Akr1a1b has been identified as a gluconeogenesis regulator via adjusting S-nitrosylation in zebrafish . This functional divergence between paralogs provides researchers with valuable insights into the evolution of the AKR1A enzyme family across species.

What criteria should be used when selecting an AKR1A1 antibody for specific applications?

When selecting an AKR1A1 antibody for research, consider these critical factors:

• Experimental application: Ensure the antibody has been validated for your intended application (WB, IP, IHC, IF/ICC). For instance, certain antibodies like the Proteintech 15054-1-AP have been validated across multiple applications including Western Blot, Immunoprecipitation, Immunohistochemistry, and Immunofluorescence .

• Species reactivity: Verify that the antibody cross-reacts with your species of interest. The commercially available antibodies have been tested for reactivity with human, mouse, and rat samples .

• Epitope recognition: Consider which region of the protein the antibody recognizes. For example, some antibodies are generated against recombinant fragment proteins within human AKR1A1 amino acids 1-150 .

• Validation data: Review published literature and validation data provided by manufacturers to ensure the antibody performs consistently across different experimental conditions.

• Clonality: Determine whether a monoclonal or polyclonal antibody better suits your experimental needs. Polyclonal antibodies like the rabbit polyclonal AKR1A1 antibodies offer good sensitivity across various applications .

The selection should be guided by your specific research question and experimental design to ensure optimal results.

How can researchers validate the specificity of an AKR1A1 antibody in their experimental system?

To validate the specificity of an AKR1A1 antibody in your experimental system, follow these methodological approaches:

• Knockout/Knockdown controls: Use CRISPR/Cas9-generated knockout models (like the akr1a1a zebrafish model ) or siRNA knockdown samples as negative controls. The observed signal should be significantly reduced or absent in these samples.

• Overexpression validation: Utilize cells overexpressing AKR1A1 to confirm increased signal intensity proportional to expression levels.

• Peptide competition assay: Pre-incubate the antibody with the immunogen peptide before application to your samples. A specific antibody will show diminished or eliminated signal when the binding sites are blocked by the competing peptide.

• Multiple antibody comparison: Test different antibodies targeting distinct epitopes of AKR1A1 to confirm consistent detection patterns.

• Cross-species reactivity testing: Since AKR1A1 is conserved across species, testing the antibody in samples from different species can provide insight into specificity based on evolutionary conservation.

• Western blot analysis: Confirm the antibody detects a protein of the expected molecular weight (calculated: 37 kDa; observed: 36 kDa) with minimal non-specific bands.

These validation steps are crucial for ensuring reliable and reproducible results in subsequent experiments.

What are the optimal tissue fixation and antigen retrieval methods for AKR1A1 immunohistochemistry?

For optimal immunohistochemical detection of AKR1A1, follow these evidence-based recommendations:

• Fixation: Standard formalin fixation (10% neutral-buffered formalin for 24-48 hours) works effectively for AKR1A1 detection in most tissues. Overfixation should be avoided as it can mask epitopes.

• Antigen retrieval: The suggested protocol involves heat-induced epitope retrieval (HIER) using TE buffer at pH 9.0. Alternatively, citrate buffer at pH 6.0 may be used, though potentially with reduced sensitivity . For optimal results:

  • Heat specimens in retrieval buffer at 95-100°C for 15-20 minutes

  • Allow gradual cooling to room temperature before proceeding with immunostaining

• Blocking: Use a 3-5% BSA or normal serum from the same species as the secondary antibody for 1 hour at room temperature to minimize background staining.

• Antibody dilution: For immunohistochemistry applications, dilute the primary AKR1A1 antibody at 1:500-1:2000, optimizing for your specific tissue type .

• Detection system: Both DAB-based chromogenic detection and fluorescence-based systems have been successfully used with AKR1A1 antibodies, with visualization parameters dependent on the specific signaling intensity in your tissue of interest.

These conditions have been optimized for detection of AKR1A1 in human thyroid cancer tissue but may require further optimization for other tissue types.

How should Western blot protocols be optimized for detection of AKR1A1 in different sample types?

For optimal Western blot detection of AKR1A1 across different sample types, implement these methodological considerations:

• Sample preparation:

  • For cell lines (like HeLa): Lyse cells in RIPA buffer supplemented with protease inhibitors

  • For tissue samples (like mouse lung): Homogenize in RIPA buffer (1:10 w/v) with protease inhibitors

  • Include phosphatase inhibitors if phosphorylation states are relevant

• Protein loading and separation:

  • Load 20-40 μg of total protein per lane

  • Separate proteins on 10-12% SDS-PAGE gels for optimal resolution around 36-37 kDa (the observed molecular weight of AKR1A1)

• Transfer conditions:

  • Use PVDF membrane for better protein retention

  • Transfer at 100V for 60-90 minutes in cold transfer buffer containing 20% methanol

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Dilute primary AKR1A1 antibody at 1:1000-1:8000 depending on sample type

  • Incubate overnight at 4°C for maximum sensitivity

  • Use HRP-conjugated secondary antibody at 1:5000-1:10000 dilution

• Detection optimization:

  • For low abundance samples: Use enhanced chemiluminescence (ECL) substrates with longer exposure times

  • For high abundance samples: Standard ECL detection with shorter exposures to avoid signal saturation

• Expected results:

  • Look for a distinct band at approximately 36 kDa

  • Verify specificity using positive controls (HeLa cells, L02 cells, mouse lung tissue)

These parameters should be adjusted based on your specific sample type and expression level of AKR1A1.

How are AKR1A1/akr1a1a knockout models generated, and what phenotypes do they exhibit?

The generation and characterization of AKR1A1/akr1a1a knockout models involve several technical approaches and reveal distinct phenotypes:

• Generation methods:

  • CRISPR/Cas9-based genome editing has been successfully employed to generate akr1a1a knockout zebrafish models . This typically involves designing guide RNAs targeting exonic regions, followed by microinjection of Cas9 protein and guide RNA into one-cell stage embryos.

  • For mammalian models, similar CRISPR/Cas9 approaches or traditional embryonic stem cell-based homologous recombination techniques have been used.

• Validation strategies:

  • Genotyping using PCR and sequencing to confirm gene disruption

  • Western blot analysis to verify the absence of protein expression

  • Enzymatic activity assays to confirm loss of function

• Observed phenotypes in akr1a1a knockout zebrafish:

  • Biochemical phenotype: Accumulated endogenous acrolein in larvae and livers of adult fish, demonstrating impaired acrolein detoxification capacity

  • Metabolic alterations: Impaired glucose homeostasis and glucose tolerance

  • Vascular abnormalities: Angiogenic retina hyaloid vasculature in larvae and angiogenic retinal vessels in adults

  • Renal changes: Glomerular basement membrane thickening consistent with early pathological findings in diabetic nephropathy

• Rescue experiments:

  • Treatment with the acrolein-scavenger L-carnosine can reverse the effects of acrolein on hyaloid vasculature in knockout models, confirming the causal relationship between acrolein accumulation and vascular phenotypes

These models provide valuable tools for investigating the physiological roles of AKR1A1/akr1a1a in vivo and understanding the pathological consequences of impaired aldehyde detoxification.

What is the relationship between AKR1A1 function and glucose homeostasis based on animal model studies?

Research using akr1a1a knockout zebrafish models has revealed significant connections between AKR1A1 function and glucose homeostasis:

• Direct experimental evidence:

  • akr1a1a knockout larvae display impaired glucose homeostasis

  • Adult akr1a1a knockout zebrafish exhibit impaired glucose tolerance

  • These metabolic disturbances are associated with accumulated endogenous acrolein due to reduced detoxification capacity

• Mechanistic pathways:

  • The loss of Akr1a1a leads to impaired insulin receptor signaling, likely due to acrolein-induced modifications of signaling proteins

  • Acrolein accumulation can directly damage cellular macromolecules through adduct formation with proteins and DNA

  • In diabetes, hyperglycemia increases the production of reactive carbonyl species that are normally detoxified by AKR1A enzymes

• Secondary complications:

  • akr1a1a knockout fish develop microvascular alterations reminiscent of diabetic complications, including angiogenic retinal vessels and glomerular basement membrane thickening

  • These findings are consistent with early pathological appearances in diabetic retinopathy and nephropathy

• Therapeutic implications:

  • Acrolein scavengers like L-carnosine can reverse some vascular phenotypes, suggesting potential therapeutic strategies for diabetic complications

  • The data strongly suggest impaired acrolein detoxification and elevated acrolein concentration as potential biomarkers and inducers for diabetes and diabetic complications

These findings highlight the crucial role of AKR1A1 in maintaining metabolic homeostasis through its detoxification functions and suggest that targeting aldehyde detoxification pathways may offer therapeutic approaches for diabetic complications.

How does AKR1A1 influence drug metabolism and chemotherapeutic efficacy?

AKR1A1 plays a significant role in drug metabolism and chemotherapeutic efficacy through several mechanisms:

• Anthracycline metabolism:

  • AKR1A1 is involved in the metabolism of anthracycline drugs including doxorubicin (DOX) and daunorubicin (DAUN)

  • The enzyme catalyzes the NADPH-dependent reduction of these drugs, potentially affecting their therapeutic efficacy and toxicity profiles

  • Genetic variants in the AKR1A1 gene that cause amino acid replacements (such as glutamate-55 to aspartate and asparagine-52 to serine) have shown reduced affinity for daunorubicin in enzymatic analyses

  • These allelic AKR1A1 variants may be associated with variations in cardiotoxic side effects of doxorubicin and daunorubicin treatments

• Combination therapy considerations:

  • All-trans-retinoic acid, which is often administered in combination with daunorubicin, effectively inhibits AKRs including AKR1A1

  • This inhibition may help sustain the therapeutic efficacy of anthracyclines by preventing their metabolic inactivation

• Procarcinogen activation:

  • AKR1A1 plays a role in the activation of procarcinogens, such as polycyclic aromatic hydrocarbon trans-dihydrodiols

  • This activation process can potentially influence carcinogenesis and the efficacy of certain chemotherapeutic agents

• Research implications:

  • Understanding AKR1A1's role in drug metabolism is crucial for personalizing chemotherapy regimens

  • AKR1A1 genotyping might help predict individual responses to anthracycline-based chemotherapy

  • Developing specific inhibitors of AKR1A1 might enhance the efficacy of certain chemotherapeutic agents

These findings highlight the importance of considering AKR1A1 expression and genetic variations in optimizing chemotherapeutic treatment strategies and understanding idiosyncratic drug responses.

What is the current understanding of AKR1A1's role in protein S-nitrosylation and how does it affect cellular signaling?

AKR1A1 plays a critical role in regulating protein S-nitrosylation, which has significant implications for cellular signaling pathways:

• Mechanism of action:

  • AKR1A1 acts as an inhibitor of protein S-nitrosylation by mediating the degradation of S-nitroso-coenzyme A (S-nitroso-CoA), which is a cofactor required for S-nitrosylation of proteins

  • The enzyme also functions as an S-nitroso-glutathione reductase by catalyzing the NADPH-dependent reduction of S-nitrosoglutathione

• Metabolic reprogramming:

  • S-nitroso-CoA reductase activity of AKR1A1 is involved in reprogramming intermediary metabolism in renal proximal tubules

  • This occurs notably by inhibiting protein S-nitrosylation of isoform 2 of pyruvate kinase M (PKM2)

  • PKM2 is a key enzyme in glycolysis, and its activity is regulated by various post-translational modifications including S-nitrosylation

• Signaling pathway integration:

  • By regulating S-nitrosylation, AKR1A1 influences multiple signaling cascades that are responsive to nitric oxide

  • This creates an intersection between redox signaling and metabolic regulation

  • In zebrafish, Akr1a1b (a paralog of Akr1a1a) has been identified as a gluconeogenesis regulator specifically through adjusting S-nitrosylation

• Physiological implications:

  • The regulation of protein S-nitrosylation by AKR1A1 represents a mechanism for fine-tuning cellular responses to nitrosative stress

  • Alterations in this regulatory mechanism may contribute to pathological states associated with dysregulated nitric oxide signaling

  • Understanding this function provides insights into how AKR1A1 influences cellular metabolism beyond its canonical role in carbonyl reduction

This emerging understanding of AKR1A1's role in protein S-nitrosylation represents a significant expansion of its recognized functions and highlights its importance at the intersection of redox biology and metabolic regulation.

What are common technical challenges when working with AKR1A1 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with AKR1A1 antibodies. Here are systematic approaches to address these issues:

• Non-specific binding and background:

  • Problem: High background staining, especially in immunohistochemistry and immunofluorescence

  • Solution: Optimize blocking conditions using 3-5% BSA or normal serum from the same species as the secondary antibody; increase washing steps; titrate antibody concentration (start with recommended 1:500-1:2000 for IHC) ; use antigen-specific peptide competition controls

• Inconsistent detection across applications:

  • Problem: Antibody performs well in some applications but not others

  • Solution: Verify the antibody has been validated for your specific application; adjust application-specific protocols (e.g., for IHC, test both TE buffer pH 9.0 and citrate buffer pH 6.0 for antigen retrieval) ; consider alternative antibody clones if necessary

• Cross-reactivity concerns:

  • Problem: Difficulty distinguishing between closely related AKR family members

  • Solution: Perform western blot analysis to confirm detection at the correct molecular weight (36 kDa for AKR1A1) ; use knockout/knockdown controls; compare results with antibodies targeting different epitopes

• Tissue-specific optimization:

  • Problem: Signal variation across different tissue types

  • Solution: Optimize fixation duration for each tissue type; adjust antigen retrieval conditions; test a range of antibody dilutions; for challenging tissues, consider alternative detection methods or signal amplification systems

• Sample preparation issues:

  • Problem: Inconsistent results between sample preparations

  • Solution: Standardize sample collection, fixation/lysis protocols, and storage conditions; include phosphatase and protease inhibitors in lysis buffers; avoid freeze-thaw cycles of antibody and samples

• Species cross-reactivity limitations:

  • Problem: Antibody doesn't perform as expected in non-validated species

  • Solution: Perform sequence alignment analysis to predict cross-reactivity; validate antibody in your species with appropriate controls; consider testing multiple antibodies targeting different epitopes

These methodological adjustments should address most technical challenges encountered when working with AKR1A1 antibodies across various experimental systems.

How can researchers design experiments to specifically investigate the acrolein detoxification function of AKR1A1/akr1a1a?

To investigate the acrolein detoxification function of AKR1A1/akr1a1a, researchers can implement these methodologically rigorous experimental designs:

• Quantification of acrolein detoxification capacity:

  • In vitro enzymatic assays using purified recombinant AKR1A1/akr1a1a and acrolein as substrate

  • Measure NADPH consumption rate spectrophotometrically (decrease in absorbance at 340 nm)

  • Compare kinetic parameters (Km, Vmax) between wild-type and mutant enzymes or across species

• Cellular models for acrolein detoxification:

  • Establish cell lines with modulated AKR1A1 expression (overexpression, knockdown, knockout)

  • Challenge cells with defined acrolein concentrations and assess:

    • Cell viability using MTT or neutral red assay

    • Protein-acrolein adduct formation using specific antibodies

    • Residual acrolein levels using derivatization techniques and HPLC analysis

• In vivo models:

  • Utilize akr1a1a knockout zebrafish models generated using CRISPR/Cas9 technology

  • Quantify endogenous acrolein using validated analytical methods in tissue samples

  • Perform rescue experiments with acrolein scavengers like L-carnosine to confirm specificity

  • Assess physiological parameters affected by acrolein accumulation (glucose homeostasis, vascular structure)

• Biomarker development:

  • Measure protein-acrolein adducts in biological samples as biomarkers of impaired detoxification

  • Develop targeted mass spectrometry methods to quantify specific acrolein-modified peptides

  • Correlate adduct levels with disease progression or metabolic parameters

• Intervention studies:

  • Test compounds that enhance AKR1A1 expression or activity

  • Evaluate acrolein scavengers as therapeutic agents in models with impaired AKR1A1 function

  • Assess improvements in hyperglycemia-associated phenotypes after interventions

These experimental approaches provide a comprehensive framework for investigating the specific role of AKR1A1/akr1a1a in acrolein detoxification and its implications for metabolic and vascular health.